The Croda – BSI partnership team in the BSI laboratories in Santiago, Chile. Credit: Business Wire / Botanical Solution Inc.

Croda Pharma has entered a strategic collaboration deal with Botanical Solution Inc (BSI) to expedite the production of sustainable pharmaceutical-grade vaccine adjuvant QS-21.

QS-21 is a potent component of adjuvant systems used in vaccines for diseases such as RSV, malaria and shingles, as well as in new vaccines and immunotherapy treatments such as cancer.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Croda Pharma and BSI will share their knowledge to bring QS-21 to market from quillaja Saponaria plant cell culture, which is made from the soap bark tree.

This is a sustainable source of QS-21, in contrast with conventional approaches that harvest mature trees.

The partnership will allow Croda Pharma to further tackle the issue of the limited sources of QS-21.

Croda Life Sciences president Daniele Piergentili stated: “[This] provides an opportunity to build a scalable and truly sustainable supply chain of QS-21 to the pharmaceutical industry.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“The plentiful supply of QS-21 enables the production of next-generation adjuvant systems for new vaccine development.”

The company stated that the collaboration aligns with its strategy to “empower biologics delivery” and follows an announcement on its earlier investments which continue its manufacturing capabilities’ expansion in the UK and the US, enabling the development of therapeutic drugs and next-generation vaccines.

Croda Adjuvant Systems managing director Peter Tygesen stated: “BSI’s unique and innovative processes for growing quillaja saponaria biomass in their labs and then extracting the QS-21 from these young plants are a game-changing approach.

“We look forward to partnering with BSI and creating a robust, scalable, and sustainable supply chain for QS-21, enabling our customers to work with this gold standard vaccine adjuvant.”